• Pregnant women - maternal age 18 years or older and capable of consenting for her own participation in this study

• Singleton pregnancy

• Sonographic evidence of gastroschisis (exteriorization of bowel content outside the fetal abdominal cavity into the amniotic cavity)

• Intraabdominal bowel dilation ≥ 8 mm at 20-24 weeks GA reviewed by prenatal ultrasound

• Absence of significant associated anomalies\* diagnosed on prenatal ultrasound or MRI

• Gestational age at the time of the procedure will be between 20 0/7 weeks and 25 6/7 weeks

• Absence of chromosomal and clinically significant abnormalities, i.e., normal karyotype and/or normal chromosomal microarray (CMA) by invasive testing (amniocentesis or Chorionic Villus Sampling (CVS)). If there is a balanced translocation with normal CMA with no other anomalies the candidate can be included. Results by fluorescence in situ hybridization (FISH) will be accepted, if the candidate's gestation age is ≥ 22 0/7 weeks. Patients declining invasive testing will be excluded

• The family has considered and declined the option of termination of the pregnancy at less than 24 weeks and of standard postnatal treatment

• The family meets psychosocial criteria (sufficient social support, ability to understand the requirements of the study)

⁃ Parental/guardian permission (informed consent) for follow up of the child after birth

‣ Significant associated anomalies are defined as such anomalies that would, in and of themselves, be life limiting or life threatening. A minor anomaly, such as a small VSD or ASD not deemed to be life limiting or threatening, or a cleft lip or other such anomaly, unless part of a genetic syndrome, will not disqualify the patient.